Synthon's most advanced pipeline program is SYD985, an ADC targeting a range of HER2-positive cancers such as (metastatic) breast cancer, gastric cancer, bladder (urothelial) cancer and endometrial (uterine) cancer.
About trial SYD985.001
Trial SYD985.001 is a two part first-in-human Phase I study with the anti-HER2 ADC SYD985 to evaluate the safety, pharmacokinetics and efficacy in patients with histologically-confirmed, locally advanced or metastatic tumors. These are patients who have progressed on standard therapy or for whom no standard therapy exists.
During part I (dose escalation), patients with solid tumors of any origin were enrolled (so called 'all comers'). For part II (expanded cohorts), enrollment includes patients with breast or selected non-breast tumors with demonstrated HER2 expression and measurable disease lesions, which are predefined in the protocol. This trial is registered in ClinicalTrials.gov with identifier NCT02277717.
Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform (Mol. Cancer Therapeutics 2014/11)partner with Synthon